Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 2. Periodic acid-Schiff’s (PAS) staining (a–h) and MUC5AC immunohistochemical staining (i–p) of normal human bronchial epithelial cells (NHBECs) incubated at the air–liquid interface with IL-13 (10 ng/mL) (a, b, d, f, g, i, j, l, n, o, q) or vehicle (PBS) (c, e, h, k, m, p) for 14 days in the presence of either an anti-IL-13Ra1 antibody (10 mg/mL) (b, c, j, k), an anti-IL-13Ra2 antibody (2.5 mg/mL) (d, e, l, m), an anti-IgG1 isotype control antibody (10 m g/mL) (f, n) or recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/mL) (g, h, o, p). None of the cells were positive after treatment with IL-13 (10 ng/mL) in the absence of the first antibody (q). White arrowheads show PAS-positive goblet cells (a, d, f). Black arrowheads show MUC5AC-positive cells (i, l, n, o). The goblet cells with secretory granules stained clearly with the PAS staining method. On the other hand, there were also surface cells that did not have any goblet cell granules but were stained with PAS, PAS-positive-but-not-goblet cells. Scale bar = 100 mm.

Article Snippet: After the NHBECs reached confluence (day 0), the cells were incubated with IL-13 (10ng/mL), IL-13 (10ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL) (R&D Systems Inc.), IL-13 (10 ng/mL) plus the rsIL-13Ra2 (4 mg/mL, R&D Systems Inc.), IL-4 (1 ng/mL), IL-4 (1 ng/mL) plus the rsIL-13Ra2 (4 mg/mL) or vehicle (PBS) for 14 days.

Techniques: Staining, Immunohistochemical staining, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 3. Number of periodic acid-Schiff’s (PAS) staining positive cells (a, PAS-positive cells), goblet cells (b), MUC5AC staining positive cells (c, MUC5AC- positive cells) and total cells (d) of normal human bronchial epithelial cells incubated with either IL-13 (10 ng/mL), IL-4 (1 ng/mL) or vehicle (PBS) for 14 days at the air–liquid interface, in the presence of either an anti-IL-13Ra1 antibody (10 mg/mL), an anti-IL-13Ra2 antibody (2.5 mg/mL), an anti-IgG1 isotype control antibody (10 mg/mL) or a recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 0.04, 0.4 or 4 mg/mL). Results are means SEM from five different bronchi. Significant differences from PBS alone are Po0.05, Po0.01 and Po0.001. Significant differences from IL-13 alone are 1Po0.05, 11Po0.01 and 111Po0.001.

Article Snippet: After the NHBECs reached confluence (day 0), the cells were incubated with IL-13 (10ng/mL), IL-13 (10ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL) (R&D Systems Inc.), IL-13 (10 ng/mL) plus the rsIL-13Ra2 (4 mg/mL, R&D Systems Inc.), IL-4 (1 ng/mL), IL-4 (1 ng/mL) plus the rsIL-13Ra2 (4 mg/mL) or vehicle (PBS) for 14 days.

Techniques: Staining, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 5. MUC5AC protein concentrations in the supernatants of normal human bronchial epithelial cell treated with IL-13 (10 ng/mL) or IL-4 (1 ng/mL) in the presence or in the absence of either an anti-IL-13Ra1 antibody (10 mg/mL) or a recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 mg/mL) for 14 days. Data are expressed as percent above control vehicle (PBS). The results are mean SEM from three different bronchi. Significant differences from PBS alone are indicated by Po0.05. Significant differences from IL-13 alone are 1Po0.05.

Article Snippet: After the NHBECs reached confluence (day 0), the cells were incubated with IL-13 (10ng/mL), IL-13 (10ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL) (R&D Systems Inc.), IL-13 (10 ng/mL) plus the rsIL-13Ra2 (4 mg/mL, R&D Systems Inc.), IL-4 (1 ng/mL), IL-4 (1 ng/mL) plus the rsIL-13Ra2 (4 mg/mL) or vehicle (PBS) for 14 days.

Techniques: Recombinant, Control

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 7. (a) and (b) The amount of MUC5AC mRNA expression in normal human bronchial epithelial cells (NHBECs) incubated with IL-13 (10 ng/mL) or vehicle of IL-13 (PBS) in the presence of an anti-IL-13Ra1 antibody (10 mg/mL) (a), an anti-IL-13Ra2 antibody (2.5 mg/mL) (b), an anti-IgG1 isotype control antibody (10 mg/mL) or a vehicle of antibodies (PBS) for 7 days. The results are the mean SEM from five different bronchi. Significant differences from the vehicle of IL-13 (PBS) (control) are Po0.01. Significant differences from IL-13 alone are 1Po0.05. (c) The amount of MUC5AC mRNA expression in NHBECs incubated with IL-13 (10 ng/mL) or a vehicle of IL-13 (PBS) in the presence of recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 0.04, 0.4 or 4 mg/mL) or a vehicle of IL-13Ra2 (PBS) for 7 days. The results are the mean SEM from five different bronchi. Significant differences from the vehicle of IL-13 (PBS) (control) Po0.01. Significant differences from IL-13 alone are indicated by 1Po0.05 and 11Po0.01. (d) The amount of MUC5AC mRNA expression in NHBECs incubated with IL-4 (0.1, 1 or 10 ng/mL) or a vehicle of IL-4 (PBS) in the presence of rsIL-13Ra2 (4 mg/mL) or a vehicle of IL-13Ra2 (PBS) for 7 days. The results are mean SEM from five different bronchi. Significant differences from the vehicle of IL-4 (PBS) (control) are Po0.01 and Po0.05.

Article Snippet: After the NHBECs reached confluence (day 0), the cells were incubated with IL-13 (10ng/mL), IL-13 (10ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL) (R&D Systems Inc.), IL-13 (10 ng/mL) plus the rsIL-13Ra2 (4 mg/mL, R&D Systems Inc.), IL-4 (1 ng/mL), IL-4 (1 ng/mL) plus the rsIL-13Ra2 (4 mg/mL) or vehicle (PBS) for 14 days.

Techniques: Expressing, Incubation, Control, Recombinant

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Article Title: Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium.

doi: 10.1111/j.1365-2222.2007.02871.x

Figure Lengend Snippet: Fig. 10. Western blot analysis of signal transducer and activator of transcription 6 (STAT6) (a) and the phosphorylated, active form of STAT6 (p-STAT6) (b) in the cell lysates of normal human bronchial epithelial cells incubated with IL-13 (10 ng/mL) or IL-4 (1 ng/mL) for 14 days. Lanes show the data from samples treated with either the vehicle of IL-13 or IL-4 (PBS) (lane 1), IL-13 (10 ng/mL) plus the vehicle of antibody (PBS) (lane 2), IL-13 plus anti-IL-13Ra1 antibody (10 mg/mL) (lane 3), IL-13 plus recombinant human soluble IL-13Ra2/Fc (rsIL-13Ra2, 4 ng/mL) (lane 4), IL-4 (1 ng/mL) plus the vehicle of antibody (PBS) (lane 5) or with IL-4 (1 ng/mL) plus rsIL-13Ra2 (4 ng/mL) (lane 6). The arrows show STAT6 (a) and p-STAT6 (b) (100120 kDa). Data are representative of three differ- ent experiments.

Article Snippet: After the NHBECs reached confluence (day 0), the cells were incubated with IL-13 (10ng/mL), IL-13 (10ng/mL) plus an anti-IL-13Ra1 antibody (10 mg/mL) (R&D Systems Inc.), IL-13 (10 ng/mL) plus the rsIL-13Ra2 (4 mg/mL, R&D Systems Inc.), IL-4 (1 ng/mL), IL-4 (1 ng/mL) plus the rsIL-13Ra2 (4 mg/mL) or vehicle (PBS) for 14 days.

Techniques: Western Blot, Incubation, Recombinant